{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT04972110",
            "orgStudyIdInfo": {
                "id": "RP-3500-03"
            },
            "organization": {
                "fullName": "Repare Therapeutics",
                "class": "INDUSTRY"
            },
            "briefTitle": "Study of RP-3500 (Camonsertib) With Niraparib or Olaparib in Advanced Solid Tumors",
            "officialTitle": "Phase 1b/2 Study of ATR InhibiTor RP-3500 and PARP Inhibitor Combinations in Patients With Molecularly Selected Cancers (ATTACC)",
            "acronym": "ATTACC",
            "therapeuticArea": [
                "Oncology and Hematology"
            ],
            "study": "study-of-rp-camonsertib-with-niraparib-or-olaparib-in-advanced-solid-tumors"
        },
        "statusModule": {
            "statusVerifiedDate": "2023-11",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2021-07-21",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2025-03",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2025-12",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2021-07-02",
            "studyFirstSubmitQcDate": "2021-07-16",
            "studyFirstPostDateStruct": {
                "date": "2021-07-22",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2023-11-02",
            "lastUpdatePostDateStruct": {
                "date": "2023-11-07",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Repare Therapeutics",
                "class": "INDUSTRY"
            },
            "collaborators": [
                {
                    "name": "Roche Pharma AG",
                    "class": "INDUSTRY"
                }
            ]
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "The primary purpose of this study is to assess the safety and tolerability of niraparib or olaparib in combination with RP-3500 (camonsertib), in patients with eligible advanced solid tumors, determine the maximum tolerated dose (MTD) of RP-3500 (camonsertib) in combination with niraparib or olaparib, examine pharmacokinetics (PK) and assess anti-tumor activity.",
            "detailedDescription": "This is a first-in-human Phase 1b/2, multi-center, open-label, dose-escalation and expansion study to:\n\n* Evaluate the safety profile and MTD of RP-3500 (camonsertib) when administered orally in combination with niraparib or olaparib to establish the recommended Phase 2 dose and schedule.\n* Characterize the PK profile of RP-3500 (camonsertib) in combination with niraparib or olaparib\n* Assess anti-tumor activity associated with RP-3500 (camonsertib) in combination with niraparib or olaparib\n* Examine biomarker responses and establish a correlation with RP-3500 (camonsertib) treatment in combination with niraparib or olaparib.\n\nAfter the RP2D and schedule is determined, expansion cohort(s) for RP-3500 (camonsertib) in combination with niraparib or olaparib will be enrolled to study the anti-tumor effect, and further examine the safety, PK, and pharmacodynamic (PD)."
        },
        "conditionsModule": {
            "conditions": [
                "Advanced Solid Tumor, Adult"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1",
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "NON_RANDOMIZED",
                "interventionModel": "SEQUENTIAL",
                "interventionModelDescription": "Dose Escalation, expansion and Phase 2",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 196,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Phase Ib Dose Escalation",
                    "type": "EXPERIMENTAL",
                    "description": "Multiple dose levels of RP-3500 (camonsertib) for oral administration in combination with niraparib and/or Multiple dose levels of RP-3500 (camonsertib) for oral administration in combination with olaparib",
                    "interventionNames": [
                        "Drug: RP-3500 (camonsertib)"
                    ]
                },
                {
                    "label": "Phase 2 Expansion Cohorts",
                    "type": "EXPERIMENTAL",
                    "description": "Expansion cohort with RP-3500 (camonsertib) + niraparib and/or Expansion cohort RP-3500 (camonsertib) + olaparib",
                    "interventionNames": [
                        "Drug: RP-3500 (camonsertib)"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "RP-3500 (camonsertib)",
                    "description": "RP-3500 (camonsertib, ATR inhibitor) in combination with niraparib or olaparib (PARP inhibitors)",
                    "armGroupLabels": [
                        "Phase 2 Expansion Cohorts",
                        "Phase Ib Dose Escalation"
                    ],
                    "otherNames": [
                        "niraparib",
                        "olaparib"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Phase Ib - Safety and Tolerability of niraparib or olaparib in combination with RP-3500 (camonsertib) by assessing the grade and frequency of adverse events and serious adverse events.",
                    "description": "To determine the safety and tolerability of niraparib or olaparib in combination with RP-3500 (camonsertib) in patients with advanced solid tumors by assessing the grade and frequency of adverse events and serious adverse events",
                    "timeFrame": "Up to 30 days after last administration of study intervention"
                },
                {
                    "measure": "Primary Phase 1b - Define Maximum Tolerated Dose of RP-3500-03 (camonsertib) in combination with niraparib or olaparib and Recommended Phase 2 Dose and preferred schedule by assessing frequency of Dose Limiting Toxicities observed at each dose level",
                    "description": "To define the Maximum Tolerated Dose of RP-3500-03 (camonsertib) in combination with niraparib or olaparib and determine Recommended Phase 2 Dose and preferred schedule by assessing the frequency of Dose Limiting Toxicities observed at each dose level",
                    "timeFrame": "At the end of cycle 1 (each cycle is 21 or 28 days)"
                },
                {
                    "measure": "Primary Phase 2 - Assess preliminary anti-tumor activity of RP-3500 (camonsertib) with niraparib or olaparib in patients with eligible advanced solid tumors",
                    "description": "To preliminarily assess the antitumor activity of RP-3500 (camonsertib) with niraparib or olaparib in patients with eligible advanced solid tumors by Response evaluation criteria (RECIST 1.1 CA-125 per GCIG, and PSA per PCWG3)",
                    "timeFrame": "While on study therapy, every 6 weeks for first 5 months and then every 9 weeks thereafter"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "To assess PK parameters of RP-3500 (camonsertib) in combination with niraparib or olaparib -Cmax",
                    "description": "To assess plasma concentrations of RP-3500 (camonsertib) and niraparib or olaparib with calculations of maximum observed plasma concentration (Cmax)",
                    "timeFrame": "Through Cycle 1 and 2 (each cycle is 21 days)"
                },
                {
                    "measure": "To assess PK parameters of RP-3500 (camonsertib) in combination with niraparib or olaparib -Tmax",
                    "description": "To assess plasma concentrations of RP-3500 (camonsertib) and niraparib or olaparib with calculations of time to maximum observed plasma concentration (Tmax)",
                    "timeFrame": "Through Cycle 1 and 2 (each cycle is 21 days)"
                },
                {
                    "measure": "To assess PK parameters of RP-3500 (camonsertib) in combination with niraparib or olaparib - AUC",
                    "description": "To assess plasma concentrations of RP-3500 (camonsertib) and niraparib or olaparib with calculations of area under the plasma concentration-time curve 0-6 hours post dose (AUC0-6).",
                    "timeFrame": "Through Cycle 1 and 2 (each cycle is 21 days)"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Male or female and \u226518 years-of-age at the time of signature of the informed consent\n* Confirmed advanced solid tumors resistant or refractory to standard treatment\n* Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1.\n* Evaluable disease as per RECIST v1.1\n* Next generation sequencing (NGS) report obtained in CLIA-certified or equivalent laboratory demonstrating eligible tumor biomarkers.\n* Submission of available tumor tissue or willingness to have a biopsy performed if safe and feasible\n* Acceptable hematologic and organ function at screening\n* Negative pregnancy test for women of childbearing potential at Screening and prior to first study drug.\n* Ability to swallow and retain oral medications.\n\nExclusion Criteria:\n\n* Prior therapy with an ATR or DNA-dependent protein kinase (DNA-PK) inhibitor.\n* Chemotherapy, small molecule anticancer or biologic anticancer therapy given within 10 days or 5 half-lives (whichever is longer), prior to first dose of study drug.\n* Use of radiotherapy (except for palliative reasons) within 7 days prior to first dose of study drug.\n* History or current condition, therapy, or laboratory abnormality that might confound the study results, or interfere with the patient's participation for the full duration of the study treatment.\n* No other anticancer therapy is to be permitted while the patient is receiving study treatment.\n* Major surgery \u226428 days or minor surgical procedures \u22647 days prior to first study treatment dose.\n* Uncontrolled, symptomatic brain metastases.\n* Uncontrolled high blood pressure\n* History of myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) diagnosis\n* Presence of other known active invasive cancers.\n* Pregnant or breastfeeding women.\n* Psychological, familial, sociological, or geographical conditions that do not permit compliance with the study protocol and/or follow-up procedures outlined in the protocol.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Gabriela Gomez, MD, MBA",
                    "role": "CONTACT",
                    "phone": "1 (857) 340-5402",
                    "email": "clininfo@reparerx.com"
                },
                {
                    "name": "Paul Basciano, MD",
                    "role": "CONTACT",
                    "phone": "1 (857) 340-5402",
                    "email": "clininfo@reparerx.com"
                }
            ],
            "locations": [
                {
                    "facility": "Participating Site #1018",
                    "status": "RECRUITING",
                    "city": "Phoenix",
                    "state": "Arizona",
                    "zip": "97401",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 33.44838,
                        "lon": -112.07404
                    }
                },
                {
                    "facility": "Participating Site #1025",
                    "status": "RECRUITING",
                    "city": "San Francisco",
                    "state": "California",
                    "zip": "94158",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 37.77493,
                        "lon": -122.41942
                    }
                },
                {
                    "facility": "Participating Site #1028",
                    "status": "RECRUITING",
                    "city": "Aurora",
                    "state": "Colorado",
                    "zip": "80012",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 39.72943,
                        "lon": -104.83192
                    }
                },
                {
                    "facility": "Participating Site #1012",
                    "status": "RECRUITING",
                    "city": "New Haven",
                    "state": "Connecticut",
                    "zip": "06511",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 41.30815,
                        "lon": -72.92816
                    }
                },
                {
                    "facility": "Participating Site #1017",
                    "status": "RECRUITING",
                    "city": "Jacksonville",
                    "state": "Florida",
                    "zip": "32224",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 30.33218,
                        "lon": -81.65565
                    }
                },
                {
                    "facility": "Participating Site #1009",
                    "status": "RECRUITING",
                    "city": "Baltimore",
                    "state": "Maryland",
                    "zip": "21205",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 39.29038,
                        "lon": -76.61219
                    }
                },
                {
                    "facility": "Participating Site #1015",
                    "status": "RECRUITING",
                    "city": "Ann Arbor",
                    "state": "Michigan",
                    "zip": "48109",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 42.27756,
                        "lon": -83.74088
                    }
                },
                {
                    "facility": "Participating Site # 1016",
                    "status": "RECRUITING",
                    "city": "Rochester",
                    "state": "Minnesota",
                    "zip": "55905",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 44.02163,
                        "lon": -92.4699
                    }
                },
                {
                    "facility": "Participating Site #1026",
                    "status": "RECRUITING",
                    "city": "New York",
                    "state": "New York",
                    "zip": "10029",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 40.71427,
                        "lon": -74.00597
                    }
                },
                {
                    "facility": "Participating Site # 1008",
                    "status": "RECRUITING",
                    "city": "New York",
                    "state": "New York",
                    "zip": "10032",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 40.71427,
                        "lon": -74.00597
                    }
                },
                {
                    "facility": "Participating Site #1029",
                    "status": "RECRUITING",
                    "city": "Eugene",
                    "state": "Oregon",
                    "zip": "97401",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 44.05207,
                        "lon": -123.08675
                    }
                },
                {
                    "facility": "Participating Site # 1001",
                    "status": "RECRUITING",
                    "city": "Houston",
                    "state": "Texas",
                    "zip": "77030",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 29.76328,
                        "lon": -95.36327
                    }
                },
                {
                    "facility": "Participating Site # 1013",
                    "status": "RECRUITING",
                    "city": "Salt Lake City",
                    "state": "Utah",
                    "zip": "84112",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 40.76078,
                        "lon": -111.89105
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "C000531550",
                    "term": "Olaparib"
                },
                {
                    "id": "C000545685",
                    "term": "Niraparib"
                }
            ],
            "ancestors": [
                {
                    "id": "D000067856",
                    "term": "Poly(ADP-ribose) Polymerase Inhibitors"
                },
                {
                    "id": "D000004791",
                    "term": "Enzyme Inhibitors"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                },
                {
                    "id": "D000000970",
                    "term": "Antineoplastic Agents"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M289466",
                    "name": "Niraparib",
                    "asFound": "PEEP",
                    "relevance": "HIGH"
                },
                {
                    "id": "M233003",
                    "name": "Olaparib",
                    "asFound": "Improvement",
                    "relevance": "HIGH"
                },
                {
                    "id": "M205",
                    "name": "Poly(ADP-ribose) Polymerase Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "M7951",
                    "name": "Enzyme Inhibitors",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "ANeo",
                    "name": "Antineoplastic Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}